Photopenic Defects in Gliomas With Amino-Acid PET and Relative Prognostic Value: A Multicentric 11C-Methionine and 18F-FDOPA PET Experience.
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
pubmed:
18
8
2020
medline:
31
12
2020
entrez:
18
8
2020
Statut:
ppublish
Résumé
The aim is to explore the concept of photopenic defects in newly diagnosed glioma patients with the 2 widely used C-MET and F-FDOPA PET amino acid tracers. Thirty-two C-MET and 26 F-FDOPA PET scans with amino acid PET-negative gliomas were selected in this European multicentric study. Of these gliomas, 16 C-MET and 10 F-FDOPA PET scans with photopenic defects were identified, exhibiting lower mean tumor-to-background ratio as compared with isometabolic gliomas (P < 0.001). Gliomas with photopenic defects had no different progression-free survival than isometabolic gliomas in the whole population (P = 0.40), but shorter progression-free survival in the subgroup of World Health Organization grade II IDH-mutant astrocytomas (35 vs 68 months; P = 0.047).
Identifiants
pubmed: 32804767
doi: 10.1097/RLU.0000000000003240
pii: 00003072-202101000-00045
doi:
Substances chimiques
fluorodopa F 18
2C598205QX
carbon-11 methionine
58576-49-1
Dihydroxyphenylalanine
63-84-3
Methionine
AE28F7PNPL
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e36-e37Références
Galldiks N, Unterrainer M, Judov N, et al. Photopenic defects on O-(2-[ 18 F]-fluoroethyl)- l -tyrosine PET: clinical relevance in glioma patients. Neuro-Oncology . 2019;21:1331–1338.
Verger A, Taieb D, Guedj E. Is the information provided by amino acid PET radiopharmaceuticals clinically equivalent in gliomas? Eur J Nucl Med Mol Imaging . 2017;44:1408–1410.
Lopci E, Riva M, Olivari L, et al. Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma. Eur J Nucl Med Mol Imaging . 2017;44:1155–1164.
Ginet M, Zaragori T, Marie P-Y, et al. Integration of dynamic parameters in the analysis of 18 F-FDOPA PET imaging improves the prediction of molecular features of gliomas. Eur J Nucl Med Mol Imaging . 2020;47:1381–1390.
Janvier L, Olivier P, Blonski M, et al. Correlation of SUV-derived indices with tumoral aggressiveness of gliomas in static 18 F-FDOPA PET: use in clinical practice. Clin Nucl Med . 2015;40:e429–e435.
Ono M, Oka S, Okudaira H, et al. Comparative evaluation of transport mechanisms of trans-1-amino-3-[ 18 F]fluorocyclobutanecarboxylic acid and l -[methyl- 11 C]methionine in human glioma cell lines. Brain Res . 2013;1535:24–37.
Youland RS, Kitange GJ, Peterson TE, et al. The role of LAT1 in (18)F-DOPA uptake in malignant gliomas. J Neurooncol . 2013;111:11–18.
Kamson DO. Hypometabolic gliomas on FET-PET—is there an inverted U-curve for survival? Neuro-Oncology . 2019;21:1221–1222.
Galldiks N, Verger A, Zaragori T, et al. Comment on “Hypometabolic gliomas on FET-PET—is there an inverted U-curve for survival?”. Neuro-Oncology . 2019;21:1612–1613.